The investigational anticancer therapeutic AG-120, which targets mutant IDH1 protein, was well tolerated and showed signs of clinical activity in patients who had advanced solid tumors positive for mutant IDH1, according ...
Nov 9, 2015
The investigational anticancer therapeutic LOXO-101, which targets a family of proteins called neurotrophic tyrosine kinase receptors (NTRKs), was safe, tolerable, and showed signs of clinical activity in patients who had ...
Nov 9, 2015
IMMU-132, an anti-Trop-2 antibody-drug conjugate (ADC) was safe, tolerable, and yielded meaningful clinical activity in heavily pretreated patients with metastatic triple-negative breast cancer (TNBC), according to data from ...
Nov 9, 2015
Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical ...
Nov 9, 2015
The epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) AZD9291 crossed the blood-brain barrier and showed clinical activity in heavily pretreated non-small cell lung cancer (NSCLC) patients with leptomeningeal ...
Nov 9, 2015
Bazedoxifene, a therapeutic approved by the U.S. Food and Drug Administration (FDA) for the prevention of osteoporosis, suppressed the growth of pancreatic tumors by inhibiting the IL-6/STAT3 signaling pathway that the cancer ...
Nov 9, 2015
For patients with colorectal cancer enrolled in a phase I clinical trial, response to the combination treatment being tested and disease progression were accurately tracked by quantifying levels of the BRAF V600E genetic ...
Nov 9, 2015
Among colorectal cancers, loss of the gene SMAD4 was significantly more common in cancers arising in the hindgut (the left side of the colon to the rectum) than in cancers arising in the midgut (the right side of the colon) ...
Nov 9, 2015
Unlike pediatric low-grade gliomas (PLGG) that are driven by BRAF fusion proteins, PLGGs that are driven by other forms of RAF fusion proteins, called CRAF fusion proteins, may not respond to single-agent therapy with FDA-approved ...
Nov 9, 2015
